Department of Clinical and Molecular Medicine, Sapienza University, Lazio, Rome, Italy.
Unitelma Sapienza University of Rome, Rome, Italy.
Expert Opin Biol Ther. 2024 May;24(5):327-333. doi: 10.1080/14712598.2024.2354386. Epub 2024 May 14.
Approximately 50% of patients that receive a CGRP(r) MoAb for the preventative treatment of migraine are expected to discontinue therapy. For patients that discontinue CGRP(r) MoAb therapy, few clinical options are available. One potential option is to switch CGRP(r) MoAbs, however, data concerning the efficacy of this intervention is scarce.
This manuscript aims to summarize all available data concerning the potential efficacy of switching CGRP(r) MoAbs following previous medication discontinuation. Data was sourced by completing a database search for the terms: 'CGRP monoclonal antibody switch OR CGRP monoclonal antibody switching.'
While data considering the potential efficacy of CGRP(r) switching continues to grow, our expert opinion supports the most recent European Headache Federation statement regarding CGRP(r) MoAb prescribing practices, concluding that there remains insufficient data to determine the efficacy of this intervention. As this topic is of significant clinical importance, we recommend a call-to-action to expand on current data considering the therapeutic options for patients that discontinue CGRP(r) MoAb therapy.
约有 50%接受 CGRP(r) 单克隆抗体预防性偏头痛治疗的患者预计会停止治疗。对于停止 CGRP(r) 单克隆抗体治疗的患者，可用的临床选择方案很少。一种潜在的选择是切换 CGRP(r) 单克隆抗体，但关于这种干预措施的疗效的数据很少。
本文旨在总结所有关于在之前停药后切换 CGRP(r) 单克隆抗体的潜在疗效的可用数据。通过搜索以下术语完成数据库搜索：“CGRP 单克隆抗体切换或 CGRP 单克隆抗体转换”。
虽然考虑 CGRP(r) 切换潜在疗效的数据继续增加，但我们的专家意见支持欧洲头痛联合会最近关于 CGRP(r) 单克隆抗体处方实践的声明，结论是仍然没有足够的数据来确定这种干预措施的疗效。由于这个话题具有重要的临床意义，我们建议采取行动，扩大目前关于停止 CGRP(r) 单克隆抗体治疗的患者的治疗选择方案的数据。
